Newly Published Article in Neurooncology Highlights Promising Drug Delivery Approach for DIPG

NEW PUBLICATION ON DR. MARK SOUWEIDANE’S DIPG TRIAL USING CONVECTION-ENHANCED DELIVERY

A team of renowned clinical researchers led by Dr. Mark Souweidane, have just published a study in Neurooncology titled “Phase 1 dose-escalation trial using convection-enhanced delivery (CED) of radio-immunotheranostic 124I-Omburtamab.” This work highlights promising results using convection-enhanced delivery (CED) to bypass the blood-brain barrier with minimal dose-escalation limits. The findings proves the procedure safe and effective at distributing a drug throughout a rare and particularly deadly pediatric brain tumor called diffuse intrinsic pontine glioma (DIPG). The median survival for DIPG is typically 8-12 months, yet several children in the trial have lived for more than three years after treatment. This results in this publication represent an important step forward in DIPG treatment.